In addition, we validated the effects of C8018‐7840 in hepatocellular carcinoma (SNU‐449 and PLC), pancreatic ductal carcinoma (PANC‐1 and SUIT‐2), and breast cancer (MDA‐MB‐231 and MCF‐7) under CCL18 treatment. The gene discussed is HSPG2; the disease is pancreatic ductal adenocarcinoma.